title: Impact of molecular profiling on clinical trial design for glioblastoma.
abstract: This review highlights the ways in which molecular and genetic profiling of malignant gliomas has led to intelligent clinical trial design. The review also highlights known resistance mechanisms to conventional therapies in malignant gliomas and potential strategies to overcome these mechanisms with the use of targeted therapy.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 3, Boston, MA 02114, USA. achakravarti@partners.org
authors.forename: Arnab
authors.initials: A
authors.lastname: Chakravarti
authors.forename: Erin
authors.initials: E
authors.lastname: Tyndall
authors.forename: Kamalakannan
authors.initials: K
authors.lastname: Palanichamy
authors.forename: Minesh
authors.initials: M
authors.lastname: Mehta
authors.forename: Kenneth
authors.initials: K
authors.lastname: Aldape
authors.forename: Jay
authors.initials: J
authors.lastname: Loeffler
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D002986:Clinical Trials as Topic; D020869:Gene Expression Profiling; D005909:Glioblastoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D012107:Research Design; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents